The consumer health sector, Barclays says, is undergoing a structural change - moving from a pricing-driven growth model toward one where volume gains drive performance. In that context, the bank highlights attributes it views as likely to separate winners from laggards: strong brands, scientifically supported products, exposure to expanding health categories, and substantial presence in emerging markets and e-commerce channels.
Unilever
Barclays points to Unilever's strategic shift toward a more concentrated health and personal care profile as a central theme. The bank notes that Unilever is building a sizable consumer health operation through a portfolio that includes Liquid I.V., OLLY and Nutrafol. According to the review, Unilever's health business has produced several years of double-digit growth, and management believes there is a pathway to roughly doubling sales over time through a mix of acquisitions and organic expansion.
The report also highlights the company's volume momentum in emerging markets, with particularly notable trends in India and Latin America. Barclays notes Unilever's valuation remains undemanding relative to peers, characterising the stock as offering a combination of growth, quality and upside potential within the consumer health universe.
Haleon
Haleon is identified as the only listed pure-play consumer health company, making it the "cleanest" listed exposure to the theme in Barclays' view. The bank lists a set of category-leading brands under Haleon's umbrella - Sensodyne, Centrum, Voltaren, Advil and ENO - and points to the company's scientific credibility, which Barclays attributes to its pharmaceutical heritage.
Beyond brand strength and scientific positioning, Barclays sees a significant margin expansion opportunity at Haleon driven by cost savings and operational improvements. The firm expects double-digit earnings growth for the business as it increases exposure to high-growth markets such as India and China, and it ranks Haleon as its highest-conviction consumer health investment in the sector review.
Danone
Barclays describes Danone as offering distinctive access to the consumer health theme through its science-led nutrition and medical nutrition divisions. The bank frames Danone at the intersection of food, health and wellness, a position that gives it exposure to longer-term demand trends including healthy ageing, disease management and specialized nutrition.
The review underscores that Danone's medical nutrition business continues to benefit from strong structural growth drivers, particularly in China. When combined with improving execution, steady organic growth and what Barclays views as an attractive valuation, Danone is characterised as an underappreciated, health-focused compounder.
The bank's selection reflects a focus on companies that pair brand and scientific strength with exposure to faster-growing regions and channels. Barclays' recommendations rest on observable company portfolios and management strategies rather than on valuation or short-term sentiment alone.